All In Biotech

Drug Trial Radar · NCT00693849

International Study to Predict Optimised Treatment - in Depression

Last checked: Nov 20, 2026Latest source record: Jul 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 2,688 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,688

Planned (sponsor's estimate)

Start

Sep 2008

Primary completion

Dec 2019

Study completion Dec 2019

Sponsor

Lead sponsor
BRC Operations Pty. Ltd.Industry
Sponsor type
Industry
First posted
Jun 9, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Health services research
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to identify genetic, physical (brain) and psychological (cognitive) markers (or combinations of them) that predict specific response to a range of antidepressants treatment (Escitalopram, Venlafaxine, Sertraline) in patients diagnosed with major depressive disorder. This study is focused on outcomes which may impact on how "personalised medicine" is implemented in depression.

Conditions

  • Major Depressive Disorder

Interventions

  • EscitalopramDrug

    10 mg/day as a single dose, increased to max 20 mg/day

  • SertralineDrug

    50 mg/day as a single dose, increased to max of 200 mg/day

  • Venlafaxine-XRDrug

    75 mg/day given once daily; increased to 150-225 mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine whether the genetic-brain-cognition function markers (or combination of markers) 'normalise' with acute drug treatment in MDDTime frame: Week 8

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • Shanti Clinical Trials

    Colton, California

  • A.D.D. Treatment Center

    Mission Viejo, California

  • Stanford University

    Stanford, California

  • Veteran Affairs/Stanford University

    Stanford, California

  • Center for Healing the Human Spirit

    Tarzana, California

  • University of Miami

    Miami, Florida

  • University of Missouri - St. Louis

    St Louis, Missouri

  • Brain Resource Center

    Englewood Cliffs, New Jersey

  • Brain Resource Center

    New York, New York

  • Weill Cornell Medical College

    White Plains, New York

  • Skyland Behavioral Health Associates , P.A.

    Asheville, North Carolina

  • Ohio State University

    Columbus, Ohio

  • NeuroDevelopment Center

    Providence, Rhode Island

  • Brain Dynamics Centre

    Westmead, New South Wales, Australia

  • Flinders University

    Adelaide, South Australia, Australia

  • Swinburne University

    Melbourne, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Brainclinics Diagnostics B.V.

    Nijmegen, Gelderland, Netherlands

  • University of Auckland

    Auckland, New Zealand

  • Brain Health Lab

    Johannesburg, Guatang, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.